DUBLIN–(BUSINESS WIRE)–The “Dry Eye Pipeline Highlights – 2018” report has been added to ResearchAndMarkets.com’s offering. Dry Eye Pipeline Highlights – 2018 provides most up-to-date information on key pipeline products in the global Dry eye market….
Author: Business Wire
Global Vision Care Market – Innovative Product Launches to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)–#Health–Technavio’s latest market research report on the global vision care market provides an analysis of the most important trends and drivers.
Zenni Optical Announces Flexible Frames Line – Expanding Its Comprehensive Eyeglass Offering for Kids and Toddlers
NOVATO, Calif.–(BUSINESS WIRE)–Zenni Optical launches a new Kids’ Flexible Glasses Collection, featuring eight unique frame styles and a virtually unbreakable design.
Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29th – May 3rd, 2018, in Honolulu, Hawaii. The scheduled times (noted in local Hawaii time) and location of the BioTime data presen
SERI Lugano: la FDA selecciona la riboflavina ParaCel para su uso como parte del protocolo de reticulación sin extirpación del epitelio para el tratamiento del queratocono
LUGANO, Suiza–(BUSINESS WIRE)–El Switzerland Eye Research Institute ha anunciado que la innovadora formulación de la riboflavina transepitelial, conocida como ParaCel, basada en la investigación de su CEO y fundador, Roberto Pinelli, MD, ha sido seleccionada entre muchas otras formulaciones por la FDA (Administración de Alimentos y Fármacos de EE. UU.) para un protocolo de reticulación (cross-linking, CXL) de colágeno corneal sin extirpación del epitelio (epi-on) en pacientes que padecen quer
SERI Lugano: la FDA selecciona la riboflavina ParaCel para su uso como parte del protocolo de reticulación sin extirpación del epitelio para el tratamiento del queratocono
LUGANO, Suiza–(BUSINESS WIRE)–El Switzerland Eye Research Institute ha anunciado que la innovadora formulación de la riboflavina transepitelial, conocida como ParaCel, basada en la investigación de su CEO y fundador, Roberto Pinelli, MD, ha sido seleccionada entre muchas otras formulaciones por la FDA (Administración de Alimentos y Fármacos de EE. UU.) para un protocolo de reticulación (cross-linking, CXL) de colágeno corneal sin extirpación del epitelio (epi-on) en pacientes que padecen quer
IDE Pivotal Trial Results for Glaukos’ iStent inject® Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery
SAN CLEMENTE, Calif. & WASHINGTON–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that two-year U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent inject® Trabecular Micro-Bypass System achieved a statistically significant reduction in unmedicated diurnal intraocul
Eye Care Leaders Showcases Entire 2015-Certified Portfolio at ASCRS/ASOA 2018
CHARLOTTE, N.C.–(BUSINESS WIRE)–#2015cehrt–Eye Care Leaders will present their comprehensive portfolio of HITRUST and 2015 certified solutions at booth #1942 at the ASCRS•ASOA Annual Symposium.
Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc.
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has filed a patent infringement lawsuit against Ivantis, Inc. in the U.S. District Court for the Central District of California, Southern Division. The lawsuit alleges that Ivantis’ Hydrus Microstent device infringes Glauko
Global Diabetic Eye Disease Devices Market – Latest Developments by Technavio
LONDON–(BUSINESS WIRE)–#MedicalDevices–Market research firm Technavio has announced the release of their latest report on the global diabetic eye disease devices market for 2018-2022.
Global Cataract Surgical Devices Market 2018-2023 – IOLs are the Most Popular Product Type – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cataract Surgical Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering. According to the report, the global cataract su…
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Congress in Washington, D.C., April 13-17, 2018. The four presentations are scheduled as follows: Saturday, April 14: 1:41 PM – 1:46 PMWalter E. Washington Convention Center – Room 143AMiosis Prevention
Compulink Showcases Innovative Mobile Patient Engagement Technology to Increase Revenue at AAOE 2018
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Compulink showcases innovative mobile patient engagement technology to increase revenue at AAOE 2018.
Dr. Nicole R. Fram of Advanced Vision Care to Present on modmed® Ophthalmology at the 2018 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting
BOCA RATON, Fla.–(BUSINESS WIRE)–Specialty-specific health information technology leader Modernizing Medicine® today announced that Nicole R. Fram, M.D. of Advanced Vision Care will present on Sunday, April 15, during the EMR Industry Spotlight Theater at the 2018 ASCRS•ASOA Annual Meeting. Dr. Fram will educate attendees about her successes utilizing the modmed Ophthalmology suite and its intelligent electronic health record (EHR) system, EMA™, including best practices providers can employ u
Global $167 Billion Eyewear Market Report 2018 with Forecasts to 2023 by Product, Gender, and Distribution Channel – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Eyewear Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering. According to the report, the global eyewear market was valued at …
Global Vision Care Market 2018-2023 – Johnson & Johnson, Cooper, Valeant Pharma, Essilor, and Novartis are Dominating – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering. According to the report, the global vision care market reache…
OMIDRIA® Added to Veterans Health Administration National Formulary
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that the Veterans Administration (VA) has added OMIDRIA® (phenylephrine and ketorolac intraocular solution 1% / 0.3%) to the VA National Formulary. The VA National Formulary is a listing of drugs and supplies that must be available at all VA facilities for the benefit of U.S. military veterans. Omeros’ commercial drug OMIDRIA is the first and only FDA-approved product to maintain pupil size by preventing intraoperative
Compulink Showcases Mobile Patient Engagement and AI-Driven EHR for Ophthalmology at ASCRS 2018
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Compulink showcases mobile patient engagement and AI-driven EHR for ophthalmology at ASCRS 2018.
Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan™
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Scott Laranjo as Director, Marketing, RoclatanTM, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Laranjo will direct future marketing activities associated w
SERI Lugano: FDA wählt ParaCel Riboflavin für die „Epi-on“-Hornhautquervernetzung zur Behandlung von Keratokonus
LUGANO, Schweiz–(BUSINESS WIRE)–Wie das Switzerland Eye Research Institute bekanntgab, wählte die FDA aus zahlreichen Alternativen die als ParaCel bekannte, bahnbrechende transepitheliale Riboflavinformulierung für die Behandlung von Patienten mit progressivem Keratokonus. ParaCel basiert auf den Resultaten der Forschungsarbeit von Dr. Pinelli, dem Gründer und CEO des Instituts. AVEDRO, Inc., Waltham, Mass. hatte 2011 alle Rechte am geistigen Eigentum erworben, die das Unternehmen zur Herstel